Metastatic Renal Cell Carcinoma Clinical Trials in Baltimore, Maryland

3 studies are recruiting for metastatic renal cell carcinoma in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

   This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland

   Locations

   328 in total

   Run by

   NRG Oncology

   See if you can join NCT05327686 on ClinicalTrials.gov

2. A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

   The researchers are doing this study to find out whether the combination of abemaciclib and cabozantinib is a safe and effective treatment for people with metastatic clear cell renal cell carcinoma (ccRCC) and translocation-associated renal cell cancer (tRCC). The researchers will test different do…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Johns Hopkins University (Data Collection Only), Baltimore, Maryland

   Locations

   8 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06835972 on ClinicalTrials.gov

3. Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

   Single arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who ha…

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT03786796 on ClinicalTrials.gov